Sodium‐glucose co‐transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta‐analysis

Abstract

Summary Several meta‐analyses have been conducted to evaluate the weight loss effect of sodium–glucose cotransporter 2 (SGLT‐2) inhibitors in patients with type 2 diabetes, whereas pooled analysis focusing on individuals without diabetes is lacking. The objective of this systematic review and meta‐analysis is to evaluate the effect of SGLT‐2 inhibitor monotherapy on weight change and cardiometabolic profiles. Multiple databases were searched for randomized controlled trials reporting weight change effect of SGLT‐2 inhibitor treatment compared with placebo for more than 12 weeks among individuals with overweight or obesity and without diabetes. A total of eight randomized controlled trials with 750 subjects were identified. SGLT‐2 monotherapy was associated with significant reduction in body weight of −2.32 kg, compared to −1.01 kg for placebo, giving a mean difference of −1.31 kg. Significant reductions in body mass index and fasting blood glucose were observed, but not for the changes in waist circumference, fat mass, blood pressure, and lipid profile compared with placebo. SGLT‐2 inhibitor monotherapy for 12 weeks or more can result in modest weight loss among people with overweight or obesity and without diabetes. Depending on pre‐existing comorbidities or risk factors, SGLT‐2 inhibitors can be considered adjuncts in the treatment of obesity.

Effect of Intermittent Fasting on Cardiometabolic Health in the Chinese Population: A Meta-Analysis of Randomized Controlled Trials

“…The primary outcome was absolute weight loss after intervention. With reference to a previous meta-analysis of RCTs that examined cardiometabolic outcomes [16], cardiometabolic parameters, including BMI, waist circumference (WC), body fat mass (BFM), total cholesterol (TC), high-density lipoproteincholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), fasting plasma glucose (FPG)/fasting glucose (GLU), homeostatic model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), and diastolic blood pressure (DBP), were selected as secondary outcomes.…”

“…Nutrients 2024, 16, 357 2 of 15 Various forms of fasting have been developed, including intermittent fasting (IF), calorie restriction, long-term fasting, very low-calorie diet, and fasting-mimicking diet [6]. In recent years, IF has been an emerging dietary intervention for weight management.…”

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial

“…Interestingly, a meta-analysis involving seven studies with 2297 participants indicated that SGLT-2 inhibitor plus MET was superior to MET for weight control in people with type 2 diabetes for no more than 52 weeks ( 43 ). Another meta-analysis of eight studies with 750 individuals found that SGLT-2 inhibitor monotherapy for 12 weeks or more could lead to modest weight loss in non-diabetic overweight and obese individuals ( 44 ). This discordance might be due to the relatively short duration of the intervention or the different diseases and populations.…”

Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

“…Besides, SGLT-2 inhibitors may also reduce the risk of retinopathy in T2DM patients 7 . In addition, SGLT-2 inhibitors have been recommended as an evidence-based therapeutic option for the management of overweight/obese patients with 8 and without T2DM 9 . These findings suggested that besides the glucose-lowering efficacy, other mechanisms may also be involved in the beneficial efficacies of SGLT-2 inhibitors on cardiorenal outcomes in T2DM patients 10 11 12 .…”

“…Original Article: Endocrine Care Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials evidence-based therapeutic option for the management of overweight/obese patients with [8] and without T2DM [9]. These findings suggested that besides the glucose-lowering efficacy, other mechanisms may also be involved in the beneficial efficacies of SGLT-2 inhibitors on cardiorenal outcomes in T2DM patients [10][11][12].…”